Stocktoria
Tango Therapeutics, Inc. TNGX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-09-03
Tango Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $62.4M | $42.1M | $36.5M | $24.9M | $37.0M |
| R&D expense | $132.2M | $143.9M | $115.2M | $105.9M | $77.6M |
| Operating income | -$111.3M | -$145.6M | -$114.2M | -$111.1M | -$58.2M |
| Income tax | $4,000 | $208,000 | $134,000 | $54,000 | $292,000 |
| Net income | -$101.6M | -$130.3M | -$101.7M | -$108.2M | -$58.2M |
| EPS (diluted) | $-0.87 | $-1.19 | $-1.08 | $-1.23 | $-0.94 |
| Operating cash flow | -$138.9M | -$131.5M | -$118.0M | -$109.1M | -$59.5M |
| Free cash flow | -$139.9M | -$132.3M | -$119.5M | -$116.8M | -$61.4M |
| Cash & equivalents | $112.3M | $69.5M | $66.4M | $60.0M | $142.7M |
| Total assets | $398.7M | $316.5M | $402.6M | $436.5M | $500.2M |
| Total liabilities | $52.5M | $117.0M | $149.5M | $187.0M | $155.4M |
| Shareholders' equity | $346.2M | $199.5M | $253.1M | $249.5M | $344.7M |
Source: SEC EDGAR filings · CIK 0001819133 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.